Clinical trials: Protease Inhibitor
Healthy Male Volunteers
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a…
- Trial name
- NCT07744386
- Testing
- Dabigatran Etexilate, Rosuvastatin, CHF10196
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Endothelial Dysfunction
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
HIV protease inhibitors (PIs) are a class of antiretroviral drugs used to inhibit viral replication. They do so by interfering with a key step in the replication process.
- Trial name
- NCT00720590
- Testing
- Atazanavir, Lopinavir/ritonavir
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indiana University
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir.
- Trial name
- NCT05064800
- Testing
- Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections, HCV Infections
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
The objective of this study is to evaluate the effect of boceprevir (steady state) on the pharmacokinetics of a single dose of raltegravir.
- Trial name
- OPAL (NCT01288417)
- Testing
- boceprevir, raltegravir
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV
The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function
Use of some protease inhibitors is associated with elevations of a blood pigment called bilirubin. This may occasionally lead to yellowing of the eyes (scleral icterus) or jaundice, but in the general population bilirubin…
- Trial name
- SSAT044 (NCT01475240)
- Where
- United Kingdom
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study
The primary objective of the study is to determine any drug interaction between the antimalarial Pyramax (pyronaridine artesunate) and the protease inhibitor ritonavir in healthy subjects.
- Trial name
- NCT01156389
- Testing
- Ritonavir and Pyramax, Pyramax
- Where
- Switzerland
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cardiopulmonary Bypass
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period.
- Trial name
- NCT00385450
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy Participants
A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions
The purpose of this study is to evaluate the single-dose pharmacokinetics and bioequivalence of darunavir 800 mg when administered as a fixed dose combination relative to 2 x 400 mg tablets of the commercial tablet formulation…
- Trial name
- NCT01619527
- Testing
- darunavir, cobicistat
- Where
- Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
HIV Infections
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in…
- Trial name
- NCT00885495
- Testing
- darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
COVID-19
Study of HS-10517 in Chinese Adult Participants
A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.
- Trial name
- NCT05779579
- Testing
- HS-10517 Dose 1, HS-10517 Dose 2, HS-10517 Dose 3
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
HIV Infections
Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures…
- Trial name
- NCT00365339
- Testing
- Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV
Genetics and HIV-1 Protease Inhibitors
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir).
- Trial name
- NCT01388543
- Testing
- Atazanavir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Healthy
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and…
- Trial name
- NCT01290211
- Testing
- Maraviroc, Fosamprenavir/ritonavir, Maraviroc + Fosamprenavir/ritonavir
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Protease Inhibitor
Atazanavir Twice Daily
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.
- Trial name
- NCT00357721
- Testing
- Atazanavir Sulphate
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light
The purpose of the study is to evaluate the potential effect of TMC435 on the sensitivity of the skin towards exposure to sunlight.
- Trial name
- NCT01124799
- Testing
- TMC435, Ciprofloxacin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir [NFV], indinavir [IDV], ritonavir soft gel capsules [RTV…
- Trial name
- NCT00005762
- Testing
- Indinavir sulfate, Ritonavir, Amprenavir
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Virus
TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration
The purpose of this study is to compare in healthy volunteers levels of TMC435 in the blood circulation after intake of 2 new capsule formulations with the level of TMC435 in the blood circulation after intake of the capsule…
- Trial name
- NCT01134718
- Testing
- TMC435 (G006), TMC435 (F021), TMC435 (G007)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland